What is Onpattro and who is it prescribed for?
Onpattro (patisiran) is prescribed for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis [1].
What is the recommended dosing and how is it given?
Onpattro is given as an intravenous infusion [1]. The prescribing information specifies the dosing schedule and instructions for administration, including infusion-related precautions [1].
What premedications and monitoring are required?
The prescribing information includes requirements for premedication and monitoring to reduce infusion-related reactions and other risks associated with dosing [1].
What are the most important warnings and contraindications?
The prescribing information lists key safety information, including boxed/major warnings (if applicable in the label) and clinically important precautions that prescribers must follow [1].
What side effects do patients commonly report?
Common adverse reactions and clinically relevant side effects are listed in the prescribing information, along with guidance on management and when to contact a clinician [1].
How does Onpattro affect vitamin A and why does it matter?
Because Onpattro can affect vitamin A levels, the prescribing information includes instructions on vitamin A supplementation and related monitoring [1].
Where can I find the official Onpattro prescribing information?
You can access the full FDA prescribing information for Onpattro from the manufacturer’s label materials and related regulatory postings [1].
Sources:
[1] https://www.drugs.com/pro/onpattro.html